TARA
Protara Therapeutics, Inc. NASDAQ Listed Oct 22, 2014$3.98
-2.21%
vs $4.07
Mkt Cap $170.5M
52w Low $2.78
25.1% of range
52w High $7.56
50d MA $4.82
200d MA $5.26
P/E (TTM)
—
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.0x
ROE
-29.2%
P/FCF
-3.0x
RSI (14)
34.40
ATR (14)
$0.24
Beta
1.50
50d MA
$4.82
200d MA
$5.26
Avg Volume
763.4K
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
345 Park Avenue South · New York City, NY 10010 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | -0.36 | -0.31 | +13.9% | 5.15 | +2.9% | +1.0% | +1.9% | -3.8% | -9.8% | -5.7% | — |
| May 11, 2026 | BMO | — | — | — | 5.27 | +0.0% | +0.0% | -2.3% | +1.0% | +1.9% | -3.8% | — |
| May 8, 2026 | BMO | — | — | — | 5.37 | -0.6% | -1.9% | +0.0% | -2.3% | +1.0% | +1.9% | — |
| May 7, 2026 | BMO | — | — | — | 5.66 | +0.0% | -5.1% | -1.9% | +0.0% | -2.3% | +1.0% | — |
| Mar 10, 2026 | BMO | -0.32 | -0.37 | -15.6% | 5.71 | -1.1% | -1.9% | -5.0% | -1.1% | +3.0% | +0.6% | — |
| Nov 10, 2025 | BMO | -0.39 | -0.31 | +20.5% | 4.53 | +1.1% | +18.3% | -1.1% | -0.6% | +4.6% | +1.1% | — |
| Aug 11, 2025 | BMO | -0.43 | -0.35 | +18.6% | 3.10 | +1.3% | -1.0% | +6.2% | -2.1% | -5.0% | +6.3% | — |
| May 8, 2025 | BMO | -0.47 | -0.29 | +38.3% | 3.37 | +0.0% | -3.9% | +0.9% | -1.5% | -2.8% | -0.6% | — |
| Mar 5, 2025 | BMO | -0.57 | -0.48 | +15.8% | 3.63 | +0.6% | +8.0% | +2.6% | -6.7% | +9.3% | -0.7% | — |
| Nov 12, 2024 | BMO | -0.50 | -0.50 | +0.0% | 2.58 | +1.2% | +4.3% | -4.1% | -4.3% | -6.5% | +0.4% | — |
| Aug 6, 2024 | BMO | -0.82 | -0.45 | +45.1% | 2.07 | +4.3% | -8.2% | +0.0% | +0.0% | +2.1% | -1.5% | — |
| May 2, 2024 | BMO | -0.99 | -0.97 | +2.0% | 2.89 | +0.7% | +0.7% | -0.3% | -1.0% | -1.4% | +5.3% | — |
| Mar 13, 2024 | BMO | -1.03 | -0.90 | +12.6% | 3.65 | +1.4% | -2.2% | +3.1% | +8.7% | +0.0% | +0.8% | — |
| Nov 3, 2023 | BMO | -1.10 | -0.87 | +20.9% | 1.35 | +4.4% | +1.5% | -13.1% | +0.0% | +0.0% | +0.0% | — |
| Aug 3, 2023 | BMO | -0.97 | -1.00 | -3.1% | 2.54 | +0.4% | -4.7% | -2.9% | +0.0% | +1.7% | +0.0% | — |
| May 4, 2023 | AMC | -1.00 | -0.80 | +20.0% | 3.05 | +0.0% | +1.0% | +0.3% | +0.6% | +4.8% | +4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.48 | $6.41 | -1.1% | -0.6% | +0.6% | +0.8% | -0.3% | +0.6% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.22 | $6.72 | +8.0% | +9.3% | +1.0% | -18.8% | +2.5% | +0.3% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.75 | $6.38 | -5.5% | -0.6% | -4.0% | +12.7% | +1.5% | +2.6% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.32 | $4.09 | -5.3% | -18.5% | -3.4% | +2.9% | -1.1% | +3.5% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.65 | +0.6% | +8.0% | +2.6% | -6.7% | +9.3% | -0.7% |
| Dec 6 | Guggenheim | Maintains | Buy → Buy | — | $6.02 | $5.66 | -6.0% | -1.8% | +12.9% | -6.3% | +0.0% | +0.0% |
| Dec 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.02 | $5.66 | -6.0% | -1.8% | +12.9% | -6.3% | +0.0% | +0.0% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.69 | $2.78 | +3.3% | -4.1% | -4.3% | -6.5% | +0.4% | -0.4% |
| Aug 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.90 | $1.91 | +0.5% | +2.1% | -1.5% | +3.7% | +3.5% | -2.0% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.90 | $1.96 | +3.2% | +0.0% | +0.0% | +2.1% | -1.5% | +3.7% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.91 | $2.88 | -1.0% | -0.3% | -1.0% | -1.4% | +5.3% | +0.7% |
| Apr 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.64 | $3.08 | +16.7% | +15.5% | -1.6% | -6.0% | +8.2% | -3.9% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.65 | +0.6% | -5.5% | -6.1% | -0.9% | -3.1% | -2.9% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.65 | $3.70 | +1.4% | -2.2% | +3.1% | +8.7% | +0.0% | +0.8% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.54 | $2.55 | +0.4% | -4.7% | -2.9% | +0.0% | +1.7% | +0.0% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.08 | $3.13 | +1.6% | +0.3% | +0.6% | +4.8% | +4.0% | -3.5% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.16 | $3.18 | +0.6% | -4.4% | +4.3% | -1.9% | -1.3% | +1.0% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.72 | $3.70 | -0.5% | -0.5% | -11.9% | -15.3% | +13.8% | -2.2% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.20 | $3.30 | +3.1% | +7.5% | +0.9% | +1.2% | -1.1% | +4.6% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.33 | $3.34 | +0.3% | -7.5% | -5.5% | -3.8% | +0.0% | +3.2% |
| Nov 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.14 | $7.29 | +2.1% | +6.0% | +2.5% | -3.0% | -1.9% | -0.7% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.26 | $10.01 | +8.1% | +10.0% | -2.6% | -0.5% | +6.5% | -4.2% |
| Nov 25 | TD Cowen | Maintains | Outperform → Outperform | — | $23.40 | $23.62 | +0.9% | +4.4% | -5.0% | +3.7% | -6.7% | +2.9% |
| Nov 25 | Guggenheim | Maintains | Buy → Buy | — | $23.40 | $23.62 | +0.9% | +4.4% | -5.0% | +3.7% | -6.7% | +2.9% |
| Oct 19 | TD Cowen | Maintains | Outperform → Outperform | — | $20.08 | $21.93 | +9.2% | +7.4% | -2.0% | +0.8% | +0.5% | +0.3% |
| Jul 29 | Guggenheim | Maintains | Buy → Buy | — | $27.45 | $28.88 | +5.2% | -6.7% | +0.7% | -3.3% | +0.4% | +4.9% |
| Jan 22 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $28.34 | $28.34 | +0.0% | +20.0% | +7.6% | -8.5% | +3.6% | -4.9% |
No insider trades available.
8-K · 2.02
!! High
Protara Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Protara Therapeutics reported financial results showing updates to its operational performance and financial condition, which investors should review for insights into the company's cash position and path to profitability.
May 13
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Protara disclosed material information via Regulation FD, suggesting a significant announcement (likely clinical, partnership, or financial news) that could immediately impact stock valuation and trading behavior.
Mar 30
8-K
Unknown — 8-K Filing
Taravant's clinical progress and anticipated 2026 milestones suggest potential catalysts for value creation, but investors should await actual regulatory approvals or trial data before committing capital to this cash-burning biotech.
Mar 10
8-K · 8.01
!! High
Protara Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Protara Therapeutics presented clinical trial data for TARA-002 showing efficacy results in BCG-unresponsive and BCG-naïve bladder cancer patients, with preliminary response assessments completed across both patient populations.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 5,207,011 | $27M | New | Mar 2026 |
| 2 | Velan Capital Investment Management Lp | 2,834,652 | $15M | — | Mar 2026 |
| 3 | Millennium Management | 2,831,208 | $15M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 2,119,018 | $11M | New | Mar 2026 |
| 5 | Aigh Capital Management Llc | 1,622,733 | $8M | New | Mar 2026 |
| 6 | Ubs Group Ag | 1,402,413 | $7M | Added | Mar 2026 |
| 7 | Point72 Asset Management | 1,152,714 | $6M | Added | Mar 2026 |
| 8 | Citadel Advisors Llc | 1,068,558 | $6M | Added | Mar 2026 |
| 9 | Adar1 Capital Management, Llc | 940,512 | $5M | New | Mar 2026 |
| 10 | Bank Of America Corp /de/ | 925,918 | $5M | Added | Mar 2026 |
| 11 | Walleye Capital Llc | 886,802 | $5M | Added | Mar 2026 |
| 12 | Assenagon Asset Management S.a. | 567,621 | $3M | Added | Mar 2026 |
| 13 | Vanguard Portfolio Management Llc | 412,604 | $2M | New | Mar 2026 |
| 14 | Northern Trust Corp | 374,852 | $2M | Added | Mar 2026 |
| 15 | Morgan Stanley | 350,658 | $2M | Added | Dec 2025 |
| 16 | Alyeska Investment Group, L.p. | 350,000 | $2M | — | Mar 2026 |
| 17 | Oppenheimer & Co Inc | 181,565 | $946K | Reduced | Mar 2026 |
| 18 | Qube Research & Technologies Ltd | 177,004 | $922K | Added | Mar 2026 |
| 19 | Cibc World Market Inc. | 175,495 | $914K | Reduced | Mar 2026 |
| 20 | Jane Street Group, Llc | 156,135 | $832K | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$170.5M
Enterprise Value
$14.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.10x
P/B
0.87x
P/S
—
P/FCF
-3.02x
EV/EBITDA
—
Shares Out
42.8M
Financials (TTM)
Revenue
$0
Net Income
-$63.3M
EBITDA
-$62.9M
Free Cash Flow
-$56.5M
Op Cash Flow
-$56.4M
EPS Basic
$-1.34
EPS Diluted
$-1.46
EPS Forward
$-1.51
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$209.5M
Total Liab.
$13.1M
Total Equity
$196.4M
Cash
$155.6M
LT Debt
$0
Book Value/Sh
$4.59
Debt/Equity
0.02x
Current Ratio
14.58
Quick Ratio
14.58
Returns & Growth
ROE
-29.2%
ROA
-27.4%
ROIC
-32.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+38.2%
Price Returns
2W
-12.3%
1M
-12.8%
3M
-26.9%
6M
-37.0%
12M
+53.0%
Technicals
52W High
$7.56
52W Low
$2.78
50d MA
$4.82
200d MA
$5.26
RSI (14)
34.40
ATR (14)
$0.24
Beta
1.50
Avg Volume
763K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 27, 2026 3:58am
· Source: financialmodelingprep.com